Clinical Trials Browser

INDUSTRY × futibatinib × Clear all

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

Gastrointestinal

Cholangiocarcinoma

NCT05827614 2026-01-23

POTENTIATE

Phase 1 Active not recruiting

85 enrolled

BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Genitourinary

Advanced and Metastatic Urothelial Cancer

NCT05727176 2025-12-29

FOENIX-CCA4

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Phase 2 Terminated

115 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Phase 1 Terminated

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung